More than 7 million Americans are now living with Alzheimer’s, according to a new report.

The Alzheimer’s Association’s 2025 Facts and Figures report, released recently, highlights a significant and concerning trend in America, indicating that over 7.2 million individuals aged 65 and older are currently diagnosed with Alzheimer's Disease. This figure represents a sharp increase, attributed partly to an aging baby boomer population, and reflects growing awareness and improved diagnostic practices. Experts like Dr. Ted Huey of Butler Hospital emphasize that the number of cases could swell to almost 14 million by the year 2050. This dramatic rise in Alzheimer’s cases includes 22,000 individuals in Rhode Island alone, stressing the need for more awareness and resources to address the impact on caregivers, who collectively provide care valued at $52 million in the state. The report underscores a historical moment in the fight against Alzheimer's, with the introduction of disease-modifying medications designed to slow the progression of Alzheimer's, offering a glimmer of hope. 79% of Americans aged 45 and older express a desire to know their Alzheimer’s status before symptoms arise. Many are open to medications, even carrying a risk of side effects, indicating a readiness to confront the disease head-on. However, within this hopeful context lies a worrying trend: budget cuts to research funding threaten to stall the promising advancements in treatment and understanding of Alzheimer’s. As stated by Dr. Huey, ceasing support at this critical juncture could hinder the momentum built in recent years. The plight of caregivers, who are generally unpaid and often face overwhelming emotional and financial burdens, cannot be overstated. In North Carolina alone, Alzheimer’s-related care is projected to cost $1.8 billion in Medicaid expenditures. Advocates like Mary Thompson emphasize the importance of early detection and proactive financial planning, revealing the real-life ramifications of the disease on family dynamics and economic stability. Furthermore, the report indicates the need for legislative support to provide better insurance coverage for biomarker testing, thereby promising improved diagnostic accuracy and timely interventions. In essence, the data presented reflects both an alarming rise in Alzheimer’s incidence and a burgeoning recognition of the disease’s implications on American families. It also highlights the shifting attitudes towards Alzheimer’s diagnosis and treatment, moving away from stigma towards a proactive strategy to manage the disease. Without doubt, this will require both grassroots advocacy and congressional action to ensure research continues and caregivers receive the support they need. The ongoing dialogue surrounding Alzheimer’s emphasizes community and familial responsibility, indicating a collective effort is essential for future progress.